1. Home
  2. BGR vs CAPR Comparison

BGR vs CAPR Comparison

Compare BGR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Energy and Resources Trust

BGR

BlackRock Energy and Resources Trust

HOLD

Current Price

$15.70

Market Cap

390.0M

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$25.80

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGR
CAPR
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.0M
1.3B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
BGR
CAPR
Price
$15.70
$25.80
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$41.38
AVG Volume (30 Days)
234.6K
912.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
6.02%
N/A
EPS Growth
N/A
N/A
EPS
0.69
N/A
Revenue
N/A
$22,270,465.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$17,308.50
P/E Ratio
$23.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.08
$4.30
52 Week High
$16.25
$40.37

Technical Indicators

Market Signals
Indicator
BGR
CAPR
Relative Strength Index (RSI) 63.65 51.08
Support Level $13.21 $25.59
Resistance Level N/A $30.06
Average True Range (ATR) 0.31 1.66
MACD 0.05 0.04
Stochastic Oscillator 68.79 53.20

Price Performance

Historical Comparison
BGR
CAPR

About BGR BlackRock Energy and Resources Trust

BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials and utilities.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: